Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
MLH1, a key DNA mismatch repair gene, has been evaluated for association with breast cancer primarily in Lynch syndrome (LS) families. In a case–control study of 423 women with germline MLH1 variants, breast cancer risk was not increased (SIR=0.87) (PMID:29345684). However, observational series identified defective MLH1 protein expression in 7 of 16 breast tumors from MLH1 mutation carriers, demonstrating mismatch repair deficiency in these cancers (PMID:20215533). A single case report described a patient with germline MLH1 c.1381A>T (p.Lys461Ter) who developed breast cancer showing loss of heterozygosity and dMMR (PMID:32040686).
Functional analyses of MLH1 truncating mutations, including c.1381A>T, revealed aberrant exon skipping and reduced full‐length transcript levels, consistent with loss‐of‐function haploinsufficiency in mismatch repair (PMID:11585727). Concordant immunohistochemistry and limited segregation data support a role for MLH1 deficiency in a subset of breast cancers arising in LS contexts. Overall, evidence for MLH1 as a breast cancer predisposition gene remains limited, and routine MLH1 testing for breast cancer risk outside LS families is not currently justified.
Key take-home: MLH1 loss contributes to breast tumorigenesis in Lynch syndrome but lacks robust epidemiological support as an independent breast cancer predisposition gene.
Gene–Disease AssociationLimitedSmall series of MLH1 mutation carriers with breast cancer (n=20 probands) and inconsistent epidemiological risk (SIR=0.87) with limited segregation and functional concordance Genetic EvidenceLimited20 breast cancer cases in MLH1 carriers; truncating variants documented but no large familial segregation Functional EvidenceLimitedMLH1 c.1381A>T leads to exon skipping and reduced transcript; MMR deficiency observed in tumor models |